ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial

Topline results demonstrated a favorable safety profile and tolerability across four ascending dose levels in healthy volunteers and showed dose dependent levels of PMN310 antibody in Cerebrospinal fluid (CSF) suggestive of its potential for target engagement in Alzheimer's disease patients PMN310 builds on a large body of scientific evidence that points to the role of soluble amyloid-beta oligomers (AbO) as a primary driver of Alzheimer's pathology. By selectively targeting toxic oligomers, ProMIS seeks to ...